Base to Base biotech podcast 53: Diagnosing autism and improving transplant outcomes

On this week’s episode, as April 2 is World Autism Day, we have a conversation with Manish Arora, CEO of LinusBio, on its test that can rule out if someone has autism, and we talk to Thomas Kledal, CEO of Synklino, about improving kidney transplantation outcomes through better cytomegalovirus (CMV) prevention.Times:03:18 LinusBio35:43 SynklinoLinusBioLinusBio has expanded access to its ClearStrand ASD test, the first non-invasive biochemical tool to rule out autism spectrum disorder (ASD), for children up to age 10. The limit was previously four years of age).Using only a strand of hair, the CLIA-certified test offers 90% sensitivity to aid early diagnosis. It is available by prescription in 49 US states.The test uses laser-based robotics to analyse biological, metabolic, and molecular patterns, and has 90% sensitivity and 95% negative predictive value for ruling out ASD.SynklinoSynklino A/S is a Danish biotechnology company pioneering transformative therapies to improve kidney transplantation outcomes through better cytomegalovirus (CMV) prevention.Preclinical data demonstrate greater than 90% reduction in CMV reactivation from latency, establishing proof-of-concept for SYN002 in human kidneys.The company recently published a preclinical study – Inhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxin – in the American Journal of Transplantation.Regulatory clearance has been granted by both UK MHRA and Health Canada for a phase 1 clinical trial of SYN002, with the Canadian study to be conducted independently by Atul Humar at UHN, Toronto.To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]